From the quarterly MD&A, Total shares plus restricted stock units is 288.209 + 1.736 = 289.945m
Multiply this by share price to give market cap about $A1300m at $4.48.
This is probably good enough, although should be adjusted for options in the money, which adds about $15 m.
Is this overvalued or undervalued?
At current cash costs seems reasonable, but they are spending a lot each quarter on sustaining capital- last quarter about $44m. This is counted as investment by the company, and takes up most of the profit at the moment.
- Forums
- ASX - By Stock
- AQG
- great buying opportunity
great buying opportunity, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AQG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online